Late Tuesday, Slack Technologies also reported what analysts called a good quarter, with revenue topping expectations. But the company reported billings that were weaker than expected, and its stock tumbled by 13.9 percent. Hopes for a potential coronavorus vaccine also helped the S&P 500 erase all of its nearly 34 percent loss from earlier in the pandemic. U.S-listed shares of AstraZeneca slipped by 2 percent Wednesday, though, after it put late-stage studies of its vaccine candidate on temporary hold while it investigates whether a recipient’s illness is a side effect of the shot.-AP

Source: The Standard September 10, 2020 00:56 UTC